<scp>Comparison of</scp>
            1064
            <scp>nm Q‐switched</scp>
            Nd:
            <scp>YAG laser and Jessner peeling in melasma treatment</scp>

Ertam, İlgen; Onur, Marakli; Oraloğlu, Göktürk; Ecem, Bulut Okut; Ünal, İdil

doi:10.1111/dth.15970

Cited by 4 publications

(3 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Then, by screening the titles and abstracts, we further eliminated 793 studies. Ultimately, 39 randomized clinical trials 12,18–55 were included in the network meta‐analysis. The flowchart of screening and selection is depicted in Figure 1.…”

Section: Resultsmentioning

confidence: 99%

Efficacy and safety of laser‐related therapy for melasma: A systematic review and network meta‐analysis

Ma,

Gao,

Liu

et al. 2023

J of Cosmetic Dermatology

View full text Add to dashboard Cite

BackgroundMelasma is a prevalent, persistent hyperpigmentation disorder that negatively affects the psychological health of patients. However, the treatment outcome remains unsatisfactory due to the complexity of pathogenesis, recurrence characteristics, and relatively high morbidity.ObjectivesTo compare the performance of laser‐related therapies in improving the melasma area severity index (MASI) score of melasma and the occurrence of adverse effects by network meta‐analysis (NMA).MethodsFrom the inception to November 2022, eligible randomized controlled trials were identified. Two investigators independently searched relevant studies from PUBMED, EMBASE, and the Cochrane Library database.ResultsA total of 39 clinical studies with 1394 participants were eligible for enrollment. For efficacy, the NMA demonstrated that Q‐switched Nd: YAG laser + topical medications (QSND+TM) was superior to Q‐switched Nd:YAG laser (QSND) [MD = −4.21 (−6.80, −1.63)], Er: YAG laser + topical medications (ERYL+TM) [MD = ‐3.52 (−6.84, −0.19)], and picosecond laser + topical medications (PICO+TM) [MD = −4.80 (−9.33, −0.27)]. The microneedling + topical medications (MN+TM) was superior to picosecond laser (PICO) [MD = −5.26 (−10.44, −0.08)] and topical medications (TM) [MD = −5.22 (−9.20, −1.23)]. The top five of the surface under the cumulative ranking curve value (SUCRA) are Q‐switched Nd:YAG laser + topical medications (QSND+TM 85.9%), oral tranexamic acid (oTA 80.1%), microneedling + topical medications (MN+TM 79.7%), Q‐switched Nd:YAG laser + intense pulse light (QSND+IPL 78.9%), and fractional carbon dioxide laser + topical medications (FCDL+TM 70.5%).ConclusionsIn conclusion, the Qs‐Nd:YAG laser with topical medications is the first choice for treating melasma according to the SUCRA value. Among the three treatment modalities, namely MN + TM, PICO, and TM, our recommendation favors MN+TM as the superior choice for enhancing the curative efficacy in melasma. However, the actual clinical choice should also take into account the adverse effects, the skin type of the patient, the duration of the disease, and other relevant factors.

show abstract

Section: Resultsmentioning

confidence: 99%

Efficacy and safety of laser‐related therapy for melasma: A systematic review and network meta‐analysis

Ma,

Gao,

Liu

et al. 2023

J of Cosmetic Dermatology

View full text Add to dashboard Cite

show abstract

“…These types of lasers target melanin and are available in multiple wavelengths, with the most commonly used being 532 nm or 1064 nm from a neodymium-doped yttrium aluminum garnet (QS-Nd:YAG) laser [32]. Recently, comparative studies were also performed on 1064 nm QS-Nd:YAG laser and Jessner's peeling, proving that these therapies are equally effective in the treatment of melasma [33]. Moreover, the skin-lightening effect achieved by laser therapy can be further sustained by using an appropriate combination therapy based on classical whitening substances, namely serums containing vitamin C, ferulic acid, and phloretin [34].…”

Section: Current Methods Of Melasma Treatmentmentioning

confidence: 99%

Cosmetic and Pharmaceutic Products with Selected Natural and Synthetic Substances for Melasma Treatment and Methods of Their Analysis

Wawrzyńczak

2023

Cosmetics

View full text Add to dashboard Cite

Melasma is a fairly common condition that is the result of hyperpigmentation caused by increased melanin secretion. In the course of melasma, certain areas of the skin become darker than the rest of the epidermis. Although the pathogenesis remains incompletely clarified, several contributing factors have been identified, namely exposure to ultraviolet and visible light, family predisposition, pregnancy, and the use of exogenous hormones. Since current beauty standards associate healthy skin with its flawless and uniform color, people strive to eliminate any unaesthetic discoloration. Cosmetic and pharmaceutical products containing active substances with a whitening effect then become helpful. The most commonly used for this purpose are hydroquinone, arbutin, retinoids, organic acids (e.g., kojic, azelaic, and ellagic), and vitamins (B3, C, and E). However, the undesirable side effects they cause and the drive to replace synthetic chemicals with their natural counterparts have resulted in numerous reports on extracts of natural origin that exhibit skin-whitening effects. The purpose of this paper is to review the most recent scientific literature, which presents active substances of natural and synthetic origin with potential for the treatment of melasma. In addition, analytical techniques that can be used for qualitative and quantitative analysis of these substances present in cosmetic and pharmaceutical products will also be presented.

show abstract

“…Compared with high fluence, greater clinical response and fewer adverse effects, including irritant and confetti hypopigmentation and postinflammatory hyperpigmentation, have been demonstrated [121]. Low-fluence 1064 nm QS Nd:YAG has comparable efficacy with TCC therapy, Jessner peeling, low-fluence Q-switched alexandrite laser (755 nm), and superior efficacy to GA peeling [121][122][123][124].…”

Section: Low-fluence Qs Nd:yagmentioning

confidence: 99%

An Update on New and Existing Treatments for the Management of Melasma

Gan,

Rodrigues

2024

Am J Clin Dermatol

View full text Add to dashboard Cite

Melasma is a chronic, acquired disorder of focal hypermelanosis that carries significant psychosocial impact and is challenging for both the patient and the treating practitioner to manage in the medium to long term. Multiple treatments have been explored, often in combination given the many aetiological factors involved in its pathogenesis. Therapeutic discoveries to treat melasma are a focal topic in the literature and include a range of modalities, with recent developments including updates on visible light photoprotection, non-hydroquinone depigmenting agents, oral tranexamic acid, chemical peels, and laser and energy-based device therapy for melasma. It is increasingly important yet challenging to remain up-to-date on the arsenal of treatments available for melasma to find an efficacious and well-tolerated option for our patients. Supplementary Information The online version contains supplementary material available at 10.1007/s40257-024-00863-2.

show abstract

Comparison of 1064 nm Q‐switched Nd: YAG laser and Jessner peeling in melasma treatment

Cited by 4 publications

References 22 publications

Efficacy and safety of laser‐related therapy for melasma: A systematic review and network meta‐analysis

Efficacy and safety of laser‐related therapy for melasma: A systematic review and network meta‐analysis

Cosmetic and Pharmaceutic Products with Selected Natural and Synthetic Substances for Melasma Treatment and Methods of Their Analysis

An Update on New and Existing Treatments for the Management of Melasma

Contact Info

Product

Resources

About